Comparative Pharmacology
Head-to-head clinical analysis: LARGON versus PROMETHAZINE VC W CODEINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LARGON versus PROMETHAZINE VC W CODEINE.
LARGON vs PROMETHAZINE VC W/ CODEINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propionazine is a phenothiazine derivative that acts as a central dopamine receptor antagonist, particularly at D2 receptors. It also exhibits antihistaminergic, anticholinergic, and sedative effects by blocking histamine H1 and muscarinic receptors.
Codeine is a prodrug converted to morphine, which acts as a mu-opioid receptor agonist inhibiting ascending pain pathways and altering pain perception. Promethazine is a phenothiazine derivative that antagonizes histamine H1 receptors, suppresses cough reflex via central action, and has anticholinergic, sedative, and antiemetic effects. Phenylephrine is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction of nasal blood vessels, reducing congestion.
50 mg intramuscularly every 4-6 hours as needed for nausea and vomiting. Maximum: 300 mg/day.
1-2 tablets orally every 4-6 hours as needed for cough and congestion. Maximum 12 tablets in 24 hours.
None Documented
None Documented
Terminal elimination half-life is 20-30 hours in healthy adults, extending up to 40-60 hours in patients with hepatic impairment or elderly.
Promethazine: 9-16 hours (range 7-20 hours) in adults; codeine: 2.5-3.5 hours (terminal) with clinical considerations for prolonged effects in hepatic impairment and CYP2D6 poor metabolizers.
Primarily renal (approximately 50-80% as unchanged drug and metabolites) via glomerular filtration and tubular secretion; minor biliary/fecal elimination (~10-15%).
Renal: 70-80% as unchanged promethazine and metabolites (including codeine and its glucuronides); biliary/fecal: 10-20%.
Category C
Category A/B
Antihistamine
Antihistamine / Antiemetic